fresolimumab + fresolimumab + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Focal Segmental Glomerulosclerosis
Conditions
Primary Focal Segmental Glomerulosclerosis
Trial Timeline
Aug 1, 2012 → Nov 1, 2014
NCT ID
NCT01665391About fresolimumab + fresolimumab + Placebo
fresolimumab + fresolimumab + Placebo is a phase 2 stage product being developed by Sanofi for Primary Focal Segmental Glomerulosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01665391. Target conditions include Primary Focal Segmental Glomerulosclerosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01665391 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Focal Segmental Glomerulosclerosis